Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting

On April 29, 2022 Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, reported that an clinical trial abstract related to ATG-008/onatasertib has been selected for presentation in the upcoming 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (2022 ASCO (Free ASCO Whitepaper)), taking place from June 3rd to 7th in Chicago, Illinois via in person or virtual attendance (Press release, Antengene, APR 29, 2022, View Source [SID1234613243]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract highlights initial results of the Phase I/II TORCH-2 study evaluating ATG-008/onatasertib in combination with toripalimab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors.

"Antengene is focused on transforming cancer care. Treatment of patients with advanced tumors and relapsed or resistant disease is a priority for us. We believe that treatment regimens that combine targeted therapies and immune-oncology agents have considerable promise in improving cancer outcomes. Specifically, we believe that the combination of ATG-008 and the PD-1 inhibitor, toripalimab, could be useful in the treatment of advanced solid tumors and so we are pleased to share the data from the TORCH-2 study with the oncology community," said Dr. Kevin Lynch, Antengene’s Chief Medical Officer.

Details for the Presentation is as follows:

Title: A phase I/II study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in patients with advanced solid tumors (TORCH-2)
Abstract: 2610
Date & time:
Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT
Sunday, June 5, 2022, 9:00 PM-12:00 midnight (Beijing Time, GMT+8)